Evogene (EVGN) Total Non-Current Liabilities (2012 - 2025)
Evogene (EVGN) posted Total Non-Current Liabilities of $4.6 million for Q4 2025, down 27.21% sequentially from $6.4 million in Q2 2025, and down 26.92% YoY from $6.3 million in Q4 2024.
Evogene (EVGN) Total Non-Current Liabilities (2012 - 2025) Analysis & Trends
Evogene has reported Total Non-Current Liabilities for 12 years, with the latest figure at $4.6 million in Q4 2025.
- Quarterly Total Non-Current Liabilities fell 26.92% year-over-year to $4.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.6 million (down 26.92% YoY) and the FY2025 annual result came in at $4.6 million, down 26.92% from the prior year.
- Total Non-Current Liabilities slipped to $4.6 million in Q4 2025 per EVGN's latest filing, from $6.4 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $15.8 million in Q2 2023 and troughed at $4.6 million in Q4 2025.
- A 5-year average of $8.6 million and a median of $6.2 million in 2021 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities surged 176.73% in 2023, then slumped 70.06% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $6.0 million in 2021, then surged by 161.76% to $15.7 million in 2022, then declined by 1.52% to $15.5 million in 2023, then plunged by 59.08% to $6.3 million in 2024, then retreated by 26.92% to $4.6 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $4.6 million, $6.4 million, and $6.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.63 Mn |
| Jun 30, 2025 | 6.36 Mn |
| Dec 31, 2024 | 6.33 Mn |
| Jun 30, 2024 | 4.74 Mn |
| Dec 31, 2023 | 15.47 Mn |
| Jun 30, 2023 | 15.84 Mn |
| Dec 31, 2022 | 15.71 Mn |
| Jun 30, 2022 | 5.72 Mn |
| Dec 31, 2021 | 6.00 Mn |
| Jun 30, 2021 | 5.57 Mn |
| Dec 31, 2020 | 5.36 Mn |
| Jun 30, 2020 | 5.31 Mn |
| Dec 31, 2019 | 5.40 Mn |
| Dec 31, 2018 | 2.96 Mn |
| Dec 31, 2017 | 3.56 Mn |
| Dec 31, 2016 | 3.47 Mn |
| Sep 30, 2013 | 7.76 Mn |
| Jun 30, 2013 | 7.76 Mn |
| Dec 31, 2012 | 7.76 Mn |